Ophthalmology

Silicon nanoneedles loaded with ocular drugs hold potential to replace invasive injections to the eye.

Age-related macular degeneration is the most common cause of vision loss in adults over age 50, but there are few treatments available. Researchers are now developing promising stem cell therapies to treat the disease.

Between invasive surgery or risky laser therapy, people suffering from severe eye floaters have no great treatment options. Now, with the development of a safer and less invasive nanoparticle-based therapy, people with floaters may finally get their vision and quality of life back.

Scientists identify a new target for treating age-related eye diseases

Roche's faricimab injected every 16 weeks proves non-inferior to aflibercept injected every eight weeks in patients with “wet” age-related macular degeneration

The acquisition includes clinical stage anti-IGF-1R monoclonal antibody VRDN-001, which is intended for treatment of thyroid eye disease

Vanda Pharmaceuticals gains FDA approval on their IND for VSJ-110 to treat allergic conjunctivitis